• BridgeBio Pharma director Hannah Valantine reported net sales of 5,004 common shares on June 22-23.
• Sales priced at USD 68 and USD 68.57; she also exercised options for 2,808 shares at USD 41.73.
• Holdings ended at 9,259 shares owned directly, with 398 shares held indirectly by spouse.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001470831-26-000635), on June 24, 2026, and is solely responsible for the information contained therein.